Recent

% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

  • dripshark dripshark Nov 16, 2012 11:51 AM Flag

    CLSN presents an opportunity

    For investors to ride along with a management team that has been putting their
    money where there mouth is by investing their own money in the stock.

    Exciting news pending:

    January 2013
     Potential FDA approval of ThermoDox for the treatment of primary liver cancer, depending on clinical results.
     Top-line release of colorectal liver metastases data from 92 patients in Phase II trials.

    Celsion Corporation (CLSN), little financial and a pipeline portfolio with a bright future. According to analyst opinions and pipeline studies, the expected target price will reach $18

    "Thermodox could work in most of cancer types. The estimations would be up to billions of dollars annually.

    On June 19, 2012, Celsion Chief Executive Michael Tardugno said:

    There is a chance if we execute perfectly here that we could be seeing an approval by the end of 2013. Certainly this is a $1 billion drug."

    Conclusion

    Celsion is a company with some very promising studies and a large potential market. It is really difficult to find a biotechnology company with such a reduced debt, but also with such advanced studies against cancer. The target price of Celsion continues to be $9 for the short term. In my opinion, Celsion could be above two digits in the long term.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CLSN
1.23-0.04(-3.15%)Aug 25 3:59 PMEDT